Expertise in
30
conditions

Dr. Hana Safah

Oncology
Office
7777 Hennessy Blvd Ste 212, 
Baton Rouge, LA 
Offers Telehealth
Expertise in
30
conditions
Office
7777 Hennessy Blvd Ste 212, 
Baton Rouge, LA 

Overview

Hana Safah is an Oncologist practicing medicine in Baton Rouge, Louisiana.

Dr. Safah is highly rated in 30 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 36 peer reviewed articles and participating in 26 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in LA

Hospital Affiliations

East Jefferson General Hospital
Our Lady Of The Lake Regional Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Office
7777 Hennessy Blvd Ste 212, Baton Rouge, LA 70808
Other Locations
Tulane University School of Medicine
1430 Tulane Ave, New Orleans, LA 70112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

26 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: May 01, 2026
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
View 9 Less Clinical Trials

36 Total Publications

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Journal: Lancet regional health. Americas
Published: March 25, 2026
Similar Doctors
Expertise in
14
conditions
Dr. Shaista Faruqui
Oncology
Expertise in
14
conditions
Dr. Shaista Faruqui
Oncology
Referral may be required

Shaista H. Faruqui M.D. Apmc

5320 Dijon Dr, 
Baton Rouge, LA 
 (0.2 miles away)
225-769-2161
Languages Spoken:
English
See accepted insurances

Shaista Faruqui is an Oncologist practicing medicine in Baton Rouge, Louisiana. Dr. Faruqui is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Idiopathic Neutropenia, Chronic Familial Neutropenia, Adult Immune Thrombocytopenia, and Immune Thrombocytopenic Purpura (ITP).

Expertise in
60
conditions
Dr. Siva Sankar
Hematology | Oncology
Expertise in
60
conditions
Dr. Siva Sankar
Hematology | Oncology
Referral may be required

Hematology Oncology Associates Of Baton Rouge

4950 Essen Ln, 
Baton Rouge, LA 
 (0.3 miles away)
225-767-0847
Languages Spoken:
English
See accepted insurances

Siva Sankar is a Hematologist and an Oncologist practicing medicine in Baton Rouge, Louisiana. Dr. Sankar is highly rated in 60 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Sickle Cell Disease, Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.

Expertise in
43
conditions
Dr. Christopher Mccanless
Oncology
Expertise in
43
conditions
Dr. Christopher Mccanless
Oncology
Referral may be required

Hematology/Oncology Clinic

8595 Picardy Ave Ste 400, 
Baton Rouge, LA 
 (2.4 miles away)
225-767-0822
Languages Spoken:
English
See accepted insurances

Christopher Mccanless is an Oncologist practicing medicine in Baton Rouge, Louisiana. Dr. Mccanless is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Bone Marrow Aspiration, and Endoscopy.

Frequently Asked Questions about Dr. Hana Safah

How do I make an appointment with Dr. Hana Safah?

You can book an appointment with Dr. Hana Safah by calling their office at 225-374-0320. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Hana Safah a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Hana Safah is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Hana Safah specialize in?

While Dr. Hana Safah is a Oncology, they have specific expertise in Multiple Myeloma, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Hana Safah participate in research or clinical trials?

Yes. Dr. Hana Safah has published 36 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Hana Safah's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Hana Safah accept my insurance?

Dr. Hana Safah accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 225-374-0320 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Safah's expertise for a condition
ConditionClose
    View All 24 Advanced Conditions
    View All 60 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile